Are Cannabis Dosing Guidelines Available for Dementia Patients?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As of 2025, there are no official NHS or NICE dosing guidelines for cannabis use in dementia care. Research and regulatory reviews confirm that cannabis-based medicinal products are not approved or recommended for treating cognitive or behavioural symptoms in dementia (NHS; NICE NG144; Alzheimer’s Society).

What NHS And NICE Guidance Says

NICE and NHS guidance specify that cannabis-based products may only be prescribed for severe epilepsy, chemotherapy-related nausea, or multiple sclerosis-related spasticity. Dementia is not listed as an approved condition. Any prescription for dementia symptoms would therefore be off-label and must occur under the supervision of a hospital specialist, with strict governance and patient safety oversight (NHS England). This means there are currently no dosing recommendations, frequency protocols, or standardised treatment pathways for dementia patients.

What Research Says About Dosing in Dementia

Clinical trials from 2023 to 2025 have investigated oral or capsule forms of cannabinoids, primarily CBD or low-dose THC/CBD combinations, to assess effects on agitation and anxiety in dementia. Results so far are inconclusive, with small studies showing limited benefit and frequent side effects such as drowsiness, confusion, and appetite changes (PubMed 2024).
Experts caution that the optimal dose for dementia has not been established, and responses vary significantly among older adults. The Alzheimer’s Society advises that any cannabis use without medical supervision carries substantial safety risks and should not replace conventional dementia treatments.

Safety And Practical Concerns

Older adults are more vulnerable to the side effects of cannabinoids due to changes in metabolism, polypharmacy, and cognitive decline. Unregulated cannabis or CBD products available online often lack dose consistency and may interact with prescribed medications, increasing the risk of confusion, sedation, or falls. NICE and NHS guidance stress the importance of evidence-based, licensed therapies before considering any experimental or unregulated products.

Clinical Bottom Line

There are no NHS or NICE dosing guidelines for cannabis in dementia care

Cannabis-based treatments for dementia are unlicensed and off-label

Clinical studies show mixed results and frequent side effects

Dosing consistency and product safety remain major concerns

Evidence-based dementia treatments should be prioritised over experimental cannabis use

AlleviMed: Understanding Medical Cannabis Frameworks

AlleviMed provides educational information about how medical cannabis is regulated and prescribed legally within the UK. Its resources explain who may be eligible, how prescriptions are governed by specialists, and why dementia is currently excluded from approved conditions. AlleviMed’s purpose is purely educational, helping patients and carers understand safe, legal, and evidence-based access pathways. For further information, visit AlleviMed.

Takeaway

There are no official or recommended cannabis dosing guidelines for dementia patients in the UK. Using cannabis without medical supervision poses significant risks, including confusion, sedation, and drug interactions. Families and carers should always seek guidance from a qualified dementia specialist before considering any unlicensed cannabis products. Evidence-based approaches such as cognitive therapies, carer support, and licensed medications remain the safest and most effective options for dementia management.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.